Effect of on 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4968-4976

  Oussenko, Irina A ^a   Holland, James F ^a   Reddy, E Premkumar ^a,b   Ohnuma, Takao ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 METHOXY 5 [(2,4,6 TRIMETHOXYSTYRYLSULFONYL)METHYL]PHENYLAMINO]ACETATE; ANTIMITOTIC AGENT; CAMPTOTHECIN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DOXORUBICIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HISTONE H2AX; ON 01910 NA; PROTEIN CDC25C; RAN GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; SULFONE DERIVATIVE; SUMO 1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CONJUGATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA DAMAGE; DRUG STRUCTURE; DRUG TARGETING; GENE ACTIVATION; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; LYMPHOMA CELL; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; GLYCINE; GTPASE-ACTIVATING PROTEINS; HUMANS; MITOSIS; PHOSPHORYLATION; POLYMERIZATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; SULFONES; SUMO-1 PROTEIN; TUBULIN;

EID: 79960390325     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1603     Document Type: Article

References (24)

1. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7:275-86. (Pubitemid 40568686)
2. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, et al. Phase 1 study of ON 01910.Na, a novel modulator of the polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-10.
3. Ohnuma T, Cho SY, Roboz J, Jiang JD, Lehrer D, Silverman L, et al. Phase I study of ON 01910.Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 2006;24:18S. Abstract nr 13137.
4. + blast counts and aneuploid clone size. Blood (ASH Annu Meet Abstr) 2009;114. Abstract nr 120.
5. Silverman LR, Odchimar-Reissig R, Navada SC, Ohnuma T, Najfeld V, Wilhelm F, et al. Effects of a novel benzyl styryl sulfone derivative ON 01910.Na on the myelodysplastic syndrome (MDS) derived clone in patients relapsing following response to azacitidine (AzaC) therapy. Blood (ASH Annu Meet Abstr) 2009;114. Abstr nr 4839.
6. Preda A, Ohnuma T, Jiang J-D, Holland JF, Reddy PE. Cross-resistance to ON 01910.Na among drug-resistant human tumor cell lines. Proc Am Assoc Cancer Res 2006;47:1106. Abstract nr 4707.
7. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006;21:3-9. (Pubitemid 43288730)
8. Oussenko I, Holland JF, Reddy EP, Ohnuma T. Modulation of Chk1, Chk2, p-Chk2 dimer and p-ATM in cancer cells treated with ON 01910.Na, a clinical stage mitotic inhibitor.Proc Am Assoc Cancer Res 2009;50. Abstract nr 2702.
9. Clarke PR, Zhang CM. Spatial and temporal coordination of mitosis by Ran GTPase. Nat Rev Mol Cell Biol 2008;9:464-77. (Pubitemid 351733403)
10. Dasso M. Emerging roles of the SUMO pathway in mitosis. Cell Div 2008;3:5-15
11. Swaminathan S, Kiendl F, Korner R, Lupetti R, Hengst L, Melchior F. RanGAP1*SUMO1 is phosphorylated at the onset of mitosis and remains associated with RanBP2 upon NPC disassembly. J Cell Biol 2004;164:965-71 (Pubitemid 38429122)
12. Sacher M, Pfander B, Jentsch S. Identification of SUMO-protein conjugates. Methods Enzymol 2005;399:392-404. (Pubitemid 41772743)
13. Minowada J, Ohnuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972;49:891-5.
14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
15. Agarwal C, Tyagi A, Agarwal R. Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther 2006;5: 3294-302. (Pubitemid 46092073)
16. Gallagher S, Winston SE, Fuller SA, Hurrell JGR. Immunoblotting and immunodetection. Curr Protoc Mol Biol 2008;83:10-28.
17. Gong J, Traganos F, Darzynkiewicz Z. Growth imbalance and altered expression of cyclins B1, A, E, and D3 in MOLT-4 cells synchronized in the cell cycle by inhibitors of DNA replication. Cell Growth Differ 1995;6:1485-93.
18. Jackman J, O'Connor PM. Synchronizing cells at the onset of S-phase by double thymidine block. Curr Protoc Cell Biol 1998; 8.3.11-2.
19. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002;22:1049-59.
20. Bonne D, Heusele C, Simon C, Pantaloni D. 40, 6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem 1985;260:2819-25. (Pubitemid 15141425)
21. Pichler A. Analysis of sumoylation. Methods Mol Biol 2008;446:131-8.
22. Mah L-J, El-Osta A, Karagiannis TC. gH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010;24: 679-86.
23. Jiang J-D, Li Y, Wang Y-L, Reddy EK, Roboz J, Ohnuma T, et al. Anticancer effects of ON-1910Na. Proc Am Assoc Cancer Res 2004; 45:1241. Abstract nr 5382.
24. Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, et al. Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer. Proc Am Assoc Cancer Res 2007;48. Abstract nr 5391.